Earle A. Chiles Research Institute
@ChilesResearch
Followers
2K
Following
6K
Media
827
Statuses
4K
The research division of Providence Cancer Institute Oregon and a Providence Center of Excellence for precision immuno-oncology and cellular therapy.
Portland, Oregon
Joined November 2012
Talented and Energetic Scientists who will Change our World - Bernard Fox @BernardAFox @ChilesResearch
https://t.co/aHLjYKW0SG
#Cancer #Medicine #Health #Oncology #OncoDaily #Scientists #Researcher #MedicalResearch #MedX #MedNews #MedEd
0
1
6
Happy to share our recently published manuscript in @ImmunologyAAI, the completion of my fellowship work @ChilesResearch in Kristina Young's lab. https://t.co/sB8d5D6y5b. Here we explore the mechanism of how TGFbR signaling modulates CD8+ T cell activity and effector function.
academic.oup.com
Abstract. Transforming growth factor beta (TGFβ) is an immunosuppressive cytokine that is overexpressed in tumor microenvironments. We have shown that CD8+
2
2
10
To all those who ran, walked, organized or volunteered during #HoodToCoast2025, especially those who did so in support of fundraising efforts for @ChilesResearch @providence, THANK YOU! And a special congrats to the indefatigable, “fibuless” @roth_becky!
0
1
6
Delighted to welcome Dr. Robert Saddawi-Konefka (@rsaddawi) as our @ChilesResearch guest speaker. RSK played a key role in demonstrating that intact draining lymphatics are essential for response to immunotherapy. He has an amazing future ahead of him! @CalifanoMd @SilvioGutkind
0
1
16
@jitcancer vision: Opportunities for deeper understanding of anti-tumor activity, toxicity & resistance to optimize cancer immunotherapy. Great work from @sitcancer visionaries including our own Dr. Will Redmond. @ChilesResearch
jitc.bmj.com
Cancer immunotherapy has radically changed the management of several malignancies, and dozens of agents have been approved in the past 15 years. While these advances have changed the field, many...
0
1
3
Great to hear about the exciting developments in TIL and CAR-T therapy for #cholangiocarcinoma
@surgeonsci @OHSUKnight #OHSUSurgOnc Dr. Eric Tran @ChilesResearch @ProvHealth
0
5
18
Holay et al. engineered INBRX-106, an OX40 agonist composed of six binding domains fused to a human IgG1 Fc. https://t.co/t46uYVaZLC @ChilesResearch
0
1
2
#SITC25 Science Preview: Join @BernardAFox @ChilesResearch, Christopher A. Klebanoff, MD @MSKCancerCenter, Rom S. Leidner, MD @ChilesResearch, Catherine Wu, MD @DanaFarber to describe novel cancer antigens derived from the dark genome. Browse details: https://t.co/RZaRt5l0N7
0
1
9
Delighted to present path response from our Neoadjuvant ImmunoRadioTherapy (NIRT-2) trial in pts w HPV- HNSCC @ASCO mPR=71% pCR=29% Downstaging=67% Omission of adjuvant RT=83% Surgical de-escalation=50% @ChilesResearch @UCSDCancer_COE @CalifanoMd
#ASCO25
https://t.co/gC3CORxI38
4
14
41
Had a great time recording a new episode of #TheImmunoVerse podcast with @BernardAFox of @ChilesResearch today at #ASCO25! 🎙️📲 Subscribe today at https://t.co/gZH9de35ST so you don’t miss this and other upcoming monthly episodes! #MoffittASCO25
0
7
16
Great to be @AHNSinfo Annual meeting. Watch for the Immunotherapy session on Wed in which @ChilesResearch IO Fellow Robert Herman will present updated survival from our Ph1 NIRT study. In addition, I will present data from KN689 during the evening sessions at 6pm!
0
2
6
Instability in regulatory T cells may predict the efficacy of cancer #immunotherapy that combines anti-PD-1 and anti-LAG-3 antibodies, according to new work involving mice and data from patients with melanoma. @ChilesResearch
https://t.co/JXulzYsb8u
0
2
8
Dr Andy Weinberg @ChilesResearch & @agon_ox opens the #TVACT2025 at @UHCancerCenter #Honolulu - 30 yrs since 1st #TVACT1995/Shows expansion of Tu-Rx CD39+/CD103+ TIL/finds 150 unique TCR in #Melanoma pt/Diverse TCR repertoire/What are they recognizing? #cancer #immunotherapy
0
3
16
Excited to be in Chicago for the @AACR Annual Meeting & very am much looking forward to the Keynote 689 presentation by @DrUppaluri, the discussion by @RobertFerrisMD & the dawn of a new era for patients with head & neck cancer. #AACR25 #FINISHCANCER @providence @ChilesResearch
The @AACR Annual Meeting is live, and we are thrilled to have members of our #FINISHCANCER team there to present their study findings! Find links to all our presentations on our blog https://t.co/OCf3xqo0vT.
#AACR25
0
3
18
Rolig and Peng et al. identified mouse tumor models with high (LAG3hi) or low (LAG3lo) frequencies of LAG3+ lymphocytes. https://t.co/lzwKY7D47x @AnnahRolig @ChilesResearch
0
1
2
The @AACR Annual Meeting is live, and we are thrilled to have members of our #FINISHCANCER team there to present their study findings! Find links to all our presentations on our blog https://t.co/OCf3xqo0vT.
#AACR25
blog.providence.org
The annual AACR meeting draws the most innovative cancer researchers seeking breakthroughs in treatments.
0
0
2
Join us at the @OncLive State of the Science Summit on April 17. Register at https://t.co/tplAoIXmPy.
registration.onclive.com
The latest in breast cancer treatment—LIVE in Portland with @providence! 📢 Join us at the State of the Science Summit on April 17 with expert insights from David M. Page, MD, Evie A. Hobbs, MD, Brie Chun, MD, and Nathalie M. Johnson, MD. Register today: https://t.co/CPckeMPjg1
0
0
0
48-year-old colorectal cancer survivor urges people to screen early. On behalf of our entire @providence #FinishCancer Team, thank you, Leslie, for your advocacy and for sharing your story of courage and grace. @KATUNews @ChilesResearch
https://t.co/U67so02whZ
katu.com
A Tillamook woman is using her diagnosis of stage three rectal cancer to educate others on the importance of early screening.
0
1
4
2025 marks a big change for us as @rbryanbell begins his new leadership roles at PCI and @ChilesResearch. He stopped by @KATUNews to share his vision for the future of cancer care. Watch https://t.co/YYAFlw7m2o.
#FINISHCANCER #immunotherapy
0
2
4
Earle A. Chiles Research Institute’s tripling of response rates for patients with head and neck cancer – @BernardAFox (@ChilesResearch/@UbiVac/@OHSUSOM) https://t.co/bO0JC32H5A
#Health #Medicine #Cancer #OncoDaily #Oncology #HeadAndNeckCancer
oncodaily.com
Bernard Fox: Earle A. Chiles Research Institute's tripling of response rates for patients with head and neck cancer / AACR2024, Bernard Fox, Bryan Bell,
0
2
23